Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Casdin Partners Master Fund, L.P., along with other related entities, reported purchasing shares of Standard Biotools Inc. NASDAQ:LAB, totaling $443,032. The purchases, executed between August 13 and August 15, 2025, were made at prices ranging from $1.2126 to $1.3104. The company, currently valued at $461 million, maintains a strong balance sheet with more cash than debt and a healthy current ratio of 5.16x. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value estimate.
Specifically, on August 13, 75,000 shares were acquired at a weighted average price of $1.3104, in multiple transactions within the range of $1.3075 to $1.3118. On August 14, an additional 133,220 shares were purchased at $1.2126 per share. The buying continued on August 15, with 150,000 shares acquired at a weighted average price of $1.2214, in multiple transactions within the range of $1.2179 to $1.2232. The stock, which has seen a -30.5% return over the past year, shows a high shareholder yield despite rapidly burning through cash.
Following these transactions, Casdin Partners Master Fund, L.P. directly owns 59,750,000 shares. Casdin Private Growth Equity Fund II, L.P. directly owns 13,939,637 shares, Casdin Private Growth Equity Fund, L.P. directly owns 2,744,219 shares and Eli Casdin directly owns 2,901,062 shares of Standard Biotools Inc.
Eli Casdin has been deputized to represent the reporting persons on the board of directors of the issuer.
In other recent news, Standard BioTools Inc. reported its first earnings results since announcing the divestiture of SomaLogic, showing a revenue beat but falling short on bottom-line expectations. The company has set a core revenue guidance between $78 million and $83 million. In a significant transaction, Standard BioTools sold its SomaLogic business to Illumina for up to $425 million in cash, including $350 million upfront and up to $75 million in milestone payments, along with royalties on certain sales. Analysts at KeyBanc have maintained a Sector Weight rating for Standard BioTools, noting the company’s challenging near-term outlook but recognizing potential for future acquisitions following the SomaLogic sale.
In another development, Precision Health Research, Singapore, selected Standard BioTools’ SomaScan 11K Assay for analyzing 100,000 plasma samples, highlighting the assay’s comprehensive proteome coverage and service quality. Additionally, the company announced restricted stock unit awards for its CEO and CFO, underlining its commitment to leadership retention. These awards are part of the company’s Amended and Restated 2011 Equity Incentive Plan. The divestiture and these strategic decisions reflect Standard BioTools’ ongoing efforts to reposition its business and strengthen its market offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.